Special Issue "Feature Papers in Cancer Biology and Anticancer Therapeutics"
Deadline for manuscript submissions: closed (31 May 2021).
2. Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan
Interests: apoptosis; NAD+ metabolism; poly(ADP-ribosyl)ation; post-translational modification; DNA replication; DNA repair; carcinogenesis; Warburg effect; neuro-inflammation; neuronal disorders; aging; transcription regulation; in silico drug design; AI medicine; anti-cancer drug; anti-inflammatory drug
We are pleased to announce the Special Issue entitled “Feature Papers in Cancer Biology and Anticancer Therapeutics”. This Special Issue aims to discuss new knowledge and share innovative ideas in the anticancer research field.
Cancer is a complex disease involving genetic/epigenetic alterations and multiple pathogenetic mechanisms. Investigation of the differential characteristics of various types of cancer cells, which distinguish them from normal cells, allows for the identification of cancer-specific targets. The principle of cancer chemo- and immune-therapies is based on the molecular targeting of the vulnerabilities of cancer cells inducing cell death by apoptosis.
In this Special Issue, we focus attention on novel target-based anticancer agents and therapeutics that exploit the vulnerabilities of cancer cells. We welcome the submission of research and review articles on the development of new anticancer agents and therapeutics.
Prof. Dr. Seiichi Tanuma
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- anticancer drugs
- cancer metabolism
- cancer inflammatory microenvironment
- cancer biomarkers
- cancer therapy